Industry › BioTech

Press Releases

エーザイ、抗アミロイドβ（Aβ）プロトフィブリル抗体「レカネマブ」について、米国において、迅速承認制度に基づく早期アルツハイマー病に対する生物製剤ライセンス申請の段階的申請を完了

May 10, 2022 11:00 JST

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

May 10, 2022 10:23 HKT/SGT

Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan

May 10, 2022 10:00 HKT/SGT

Novotech收購美國合同研究組織(CRO)，拓展全球專業領域

May 05, 2022 09:00 HKT/SGT

Novotech收购美国合同研究组织(CRO)，拓展全球专业领域

May 05, 2022 09:00 HKT/SGT

노보텍, 미국 임상시험수탁기관 인수 - 글로벌 전문성 확대

May 05, 2022 09:00 HKT/SGT

Novotech Acquires US CRO NCGS, Expands Global Expertise

May 05, 2022 09:00 HKT/SGT

Avantor Announces Investment in Manufacturing and Distribution Hub in Singapore to Serve Rapidly Growing Asia Pacific Biopharma Industry

May 05, 2022 04:05 HKT/SGT

Malaysian Genomics Resource Centre Berhad Supports Yayasan Seri Negara's Ramadhan Initiative

Apr 28, 2022 11:30 HKT/SGT

エーザイ、「レカネマブ」の早期アルツハイマー病当事者様に対する長期的健康アウトカムについてシミュレーションを用いた評価結果がNeurology and Therapy誌に掲載

Apr 28, 2022 10:00 JST

エーザイ、企業価値・株主共同の利益の確保に関する対応方針（買収防衛策）の非継続（廃止）について

Apr 28, 2022 10:00 JST

Legend Capital's Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis

Apr 27, 2022 16:09 HKT/SGT

CNN「Mission: Ahead」人命救助のためにテクノロジーの限界に挑戦する先駆者と出会う

Apr 27, 2022 10:45 JST

CNN「Mission: Ahead」人命救助のためにテクノロジーの限界に挑戦する先駆者と出会う

Apr 27, 2022 10:45 JST

Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022

Apr 26, 2022 18:07 HKT/SGT

君联资本联合创建企业朗信生物遗传性视网膜变性基因治疗产品在中国获批临床

Apr 24, 2022 17:02 HKT/SGT

君聯資本聯合創建企業朗信生物遺傳性視網膜變性基因治療產品在中國獲批臨床

Apr 24, 2022 17:01 HKT/SGT

Legend Capital's Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China

Apr 24, 2022 17:00 HKT/SGT

医思健康料全年销售额超30亿港元按年增逾35%

Apr 21, 2022 09:09 HKT/SGT

醫思健康料全年銷售額超30億港元按年增逾35%

Apr 21, 2022 09:08 HKT/SGT